CLAIMS

~~We claim:~~

1. Use of ~~A method of treating cancer in a subject in need thereof, comprising administering an effective amount of~~ Conjugate **1** or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a subject, wherein the Conjugate **1** or a pharmaceutically acceptable salt thereof is to be administered to the subject at a dose of 150 mg/m^2, 175 mg/m^2, or 200 mg/m^2 body surface area.

2. Use of ~~A method of treating cancer in a subject in need thereof, comprising administering an effective amount of~~ Conjugate **1** or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a ~~to the~~ subject, wherein the subject has received at least one previous anticancer therapy.

3. Use of ~~A method of treating cancer in a subject in need thereof, comprising administering an effective amount of~~ Conjugate **1** or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a ~~to the~~ subject, wherein the subject shows partial response or stable disease after the treatment.

4. The ~~method~~ use of any one of claims 1, 2 or 3, wherein the dose of Conjugate **1** or a pharmaceutically acceptable salt thereof is 175 mg/m^2.

5. The ~~method~~ use of claim 4, wherein Conjugate **1** or a pharmaceutically acceptable salt thereof is to be administered once a week for 3 weeks on Day 1, Day 8, and Day 15 followed with one week of no treatment.

6. The ~~method~~ use of any one of claims 1, 2 or 3, wherein the cancer is selected from the group consisting of a cancer of anus, breast, cholangiocarcinoma, colon, Ewing sarcoma, liver, lung, neuroendocrine, ovary, pancreas, salivary gland, and sarcoma.

7. The ~~method~~ use of any one of claims 1, 2 or 3, wherein the cancer is pancreatic adenocarcinoma, endometrial adenocarcinoma, liposarcoma, or squamous cell carcinoma of the anus, cervix, or head and neck.

8. The ~~method~~ use of any one of claims 1, 2 or 3, wherein the ratio of the tumor Conjugate **1** level to the plasma Conjugate **1** level is more than 5.

9. The ~~method~~ use of any one of claims 1, 2 or 3, wherein the tumor Conjugate **1** level is more than 300 nM.

10. The ~~method~~ use of any one of claims 1, 2 or 3, wherein the ratio of the tumor SN-38 level to the plasma SN-38 level is more than 3.

11. The ~~method~~ use of any one of claims 1, 2 or 3, wherein the tumor SN-38 level is more than 80 nM.

12. The ~~method~~ use of claim 1, wherein the subject further receives at least one PARP inhibitor treatment.

13. The ~~method~~ use of claim 12, wherein the PARP inhibitor is to be administered on Days 2, 3, 4, 5 and 6 of a 7-day cycle.

14. The ~~method~~ use of claim 12, wherein the PARP inhibitor is talazoparib.

15. The ~~method~~ use of claim 12, wherein the cancer is small cell lung cancer.

16. The ~~method~~ use of claim 12, wherein the subject is HPV positive.

17. The ~~method~~ use of claim 1, wherein the subject further receives 5-FU, leucovorin, or a combination of 5-FU and leucovorin.

18. Conjugate **1** or a pharmaceutically acceptable salt thereof, for use in therapy.